Psychopharmacology News and Research

RSS

Psychopharmacology is the study of drug-induced changes in mood, sensation, thinking, and behavior.

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Psychopharmacology expert calls for more mental health staffing at army bases

The recent shootings at the Ft. Hood, Texas army base, allegedly by an army psychiatrist, have placed much-needed focus on mental health care in the army. In an article published in the December issue of the journal CNS Spectrum, renowned psychopharmacology expert Stephen M. Stahl, MD, PhD, calls for increased mental health staffing at Fort Hood and other army bases.

14 Dec 2009

Study provides new insight on teens’ addiction to drug abuse

It is common knowledge that smoking is a health risk but why do teens become addicted to smoking more easily than adults? In an evaluation for Faculty of 1000 Biology, Neil Grunberg looks into why adolescents are more prone to substance abuse.

14 Dec 2009

Rats exposed to passive smoking become dependent on nicotine, reveals study

Rats passively exposed to tobacco smoke become dependent on nicotine, according to a new study by Dr. Adrie Bruijnzeel and colleagues from the University of Florida in the US. Their findings of how rats' brains respond to exposure to tobacco smoke have implications for the study of the effects of tobacco smoke on the human brain even from passive exposure to other smokers, and for future studies testing new treatments for tobacco addiction. Their work has just been published online in Springer's journal Psychopharmacology.

9 Dec 2009

Antipsychotic medications increase the levels of inflammation markers, find researchers

Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia.

2 Dec 2009

Behavior problems in children with autism can be reduced with a training program for parents

The serious behavior problems that can occur in children with autism and related conditions can be reduced with a treatment plan that includes medication combined with a structured training program for parents, according to Yale University researchers and their colleagues.

26 Nov 2009

New findings suggest current system of classifying psychoactive drugs in UK may need to be revisited

Drug users are well informed about the harms associated with the drugs they use, and perceive alcohol and tobacco to be amongst the most dangerous substances, according to a survey by UCL (University College London) and Imperial College London researchers.

25 Nov 2009

Shire publishes new study results on INTUNIV Extended-Release Tablets

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone.

17 Nov 2009

Potential benefits of Labopharm's novel trazodone formulation published

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.

11 Nov 2009

Shire's INTUNIV for treating ADHD now available in the U.S.

Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.

9 Nov 2009

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

CNS Response, Inc. announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEG®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.

29 Oct 2009

Journal publishes Hythiam's PROMETA treatment program results

Hythiam, Inc. announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the Journal of Clinical Psychopharmacology, a leading scholarly publication in psychopharmacology that features articles reporting on clinical trials and studies.

29 Sep 2009

Late diagnosis of bipolar disorder in children and adults

75% of the cases of paediatric bipolar disorder are diagnosed late - up to 18 months - due to the symptoms manifesting themselves in a different manner depending on whether the patient is a child or adult. Moreover, 25% of sufferers have a delay in their medical diagnoses of up to three years and four months, according to a study by the Department of Psychiatry and Medical Psychology at the University Hospital of Navarra, in collaboration with the Paediatric Psychopharmacology Unit at the l Massachusetts General Hospital at Harvard University (Boston, United States).

22 Sep 2009

Scientific program to treat and prevent mental disorders

Mental disorders are a global problem and represent one of the biggest challenges for health care systems. In the world, there are some 500 million people suffering from mental disorders, and in the European Union, mental disorders range as one of the leading causes of disease burden.

14 Sep 2009

Research to develop new techniques for studying wild and transgenic mice's nervous system

Researchers of the Pablo de Olavide University (Seville) have started different projects based on the study of phenotype techniques in mice and their applicability to the pharmaceutical industry and neurodegenerative medicine.

8 Sep 2009

ABAM addresses the need for treating patients with addiction issues by introducing a new certification

The American Board of Addiction Medicine (ABAM) has addressed the significant need for treatment of patient's with addiction issues through the establishment of a new certification in the field of addiction medicine. Cesar L. Benarroche, MD is among the first physicians in the United States certified by the American Board of Addiction Medicine, a new independent medical specialty board.

29 Aug 2009

Jealousy in relationships fuelled by Facebook!

The more time college students spend on Facebook, the more likely they are to feel jealous toward their romantic partners, leading to more time on Facebook searching for additional information that will further fuel their jealousy, in an escalating cycle that may become addictive, according to a study reported in CyberPsychology & Behavior, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/cpb

6 Aug 2009